Anderson T D, Davidovich A, Feldman D, Sprinkle T J, Arezzo J, Brosnan C, Calderon R O, Fossom L H, DeVries J T, DeVries G H
Department of Toxicology and Pathology, Hoffmann-La Roche Inc., Nutley, New Jersey.
Lab Invest. 1994 May;70(5):724-39.
The reverse transcriptase inhibitor, 2',3'-dideoxycytidine (ddC), causes a dose-limiting peripheral neuropathy in humans, the mechanism of which is unknown. Rabbits given ddC develop peripheral myelinopathy and axonopathy, but it has not been determined if either the myelin or axonal changes are primary or if they occur concurrently.
To characterize sequential development of the ddC-induced neuropathy, 40 rabbits were given either vehicle or ddC by oral intubation at a dose of 35 mg/kg per day for 24 weeks. Electrophysiologic studies, pathologic examination of peripheral and central nervous system and skeletal muscle, and biochemical analysis of the sciatic nerve were performed at baseline (electrophysiology only) and after 8, 12, 16, 20, and 24 weeks of treatment.
Neuropathologic changes in peripheral nerves were first evident at 16 weeks and were more pronounced at 20 and 24 weeks; onset of paresis occurred at week 20, whereas clear electrophysiologic deficits were seen only at week 24. Electrophysiologic changes were prolonged F-waves (measure of proximal motor conduction) and minor changes in distal conduction measurements. Pathologic changes included myelin splitting, intramyelinic edema, demyelination, and remyelination of the largest diameter nerve fibers in the ventral root and sciatic nerve. Axonal degeneration and reduction in axonal diameter were seen. Enlarged mitochondria with abnormal ultrastructure were present in Schwann cells of those animals with a myelinopathy. Mitochondrial abnormalities or other signs of degeneration were not seen in neurons of the dorsal root ganglia or in skeletal muscle. Significant changes were not present in myelin protein composition, myelin lipid composition, or activity of the myelin-specific enzyme 2',3'-cyclic nucleotide 3'-phosphohydrolase. Major reductions in levels of protein zero (P0, the homophilic adhesion protein of myelin) were not seen; however, the turnover rate of P0 was reduced as P0 messenger RNA expression in ddC-treated sciatic nerves decreased to 30 to 50% of control values.
The peripheral neuropathy caused by ddC in rabbits is characterized as a myelinopathy of the proximal portion of the nerve fibers and as an axonopathy involving both proximal and distal fibers. The myelinopathy was associated with enlarged and abnormally shaped mitochondria in Schwann cells and is consistent with an effect of ddC on structure and function of Schwann cell mitochondria. Altered Schwann cell metabolism was evident by reduced levels of P0 messenger RNA, loss of homophilic myelin adhesion at the intraperiod line, and subsequent intramyelinic edema. Because axonal degeneration occurred concurrently with the myelin changes, it could not be determined if axonal changes were secondary to serve myelinic edema or if they represented a primary effect of ddC on neurons.
逆转录酶抑制剂2',3'-双脱氧胞苷(ddC)可导致人类出现剂量限制性周围神经病变,其机制尚不清楚。给予ddC的兔子会发生周围性髓鞘病和轴索性病变,但尚未确定髓鞘或轴索变化是原发性的,还是同时发生的。
为了描述ddC诱导的神经病变的连续发展过程,40只兔子通过口服插管给予溶媒或ddC,剂量为每天35mg/kg,持续24周。在基线(仅电生理学)以及治疗8、12、16、20和24周后,进行电生理研究、外周和中枢神经系统及骨骼肌的病理检查,以及坐骨神经的生化分析。
周围神经的神经病理变化在16周时首次明显,在20周和24周时更明显;轻瘫在第20周出现,而明显的电生理缺陷仅在第24周出现。电生理变化为F波延长(近端运动传导的指标)和远端传导测量的轻微变化。病理变化包括髓鞘分离、髓鞘内水肿、脱髓鞘以及腹根和坐骨神经中最大直径神经纤维的再髓鞘化。可见轴突变性和轴索直径减小。患有髓鞘病的动物的施万细胞中存在线粒体增大且超微结构异常。背根神经节的神经元或骨骼肌中未见线粒体异常或其他变性迹象。髓鞘蛋白组成、髓鞘脂质组成或髓鞘特异性酶2',3'-环核苷酸3'-磷酸水解酶的活性没有显著变化。未观察到蛋白零(P0,髓鞘的同种亲和粘附蛋白)水平的大幅降低;然而,随着ddC处理的坐骨神经中P0信使RNA表达降至对照值的30%至50%,P0的周转率降低。
ddC在兔子中引起的周围神经病变的特征是神经纤维近端的髓鞘病以及涉及近端和远端纤维的轴索性病变。髓鞘病与施万细胞中线粒体增大和形状异常有关,并且与ddC对施万细胞线粒体结构和功能的影响一致。施万细胞代谢改变表现为P0信使RNA水平降低、周期内线处同种亲和髓鞘粘附丧失以及随后的髓鞘内水肿。由于轴突变性与髓鞘变化同时发生,因此无法确定轴索变化是继发于髓鞘水肿还是代表ddC对神经元的原发性作用。